Primers on Molecular Pathways

Despite tremendous scientific effort, conventional treatment approaches have had little impact on the course of pancreatic ductal adenocarcinoma. Therefore, urgency is needed to understand the molecular mechanisms underlying the development of pancreatic cancer with the hope that this will lead to preventative and treatment strategies to improve the outcome of the disease. Numerous factors contribute to progression of this disease, including constitutively active NFĸB, which has been shown to positively influence cancer cell survival, proliferation, invasion, metastasis and chemoresistance. Recently, the cytoplasmic serine/threonine protein kinase glycogen synthase kinase-3β (GSK-3β) was found to regulate NFĸB activation and the proliferation and survival of pancreatic cancer cells. Moreover, recent studies in other human malignancies have implicated GSK-3β as a regulator of cancer cell proliferation, survival and chemoresistance through distinct mechanisms. Thus, GSK-3β has emerged as a viable therapeutic target in the treatment of several human neoplasms.

[1]  N. Kay,et al.  Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. , 2007, Blood.

[2]  T. Smyrk,et al.  Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3β in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation , 2006, Clinical Cancer Research.

[3]  Xin Lu,et al.  Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells , 2006, Cell Research.

[4]  J. Salles,et al.  A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia , 2006, Oncogene.

[5]  M. V. Van Dyke,et al.  Tumour necrosis factor‐α depletes histone deacetylase 1 protein through IKK2 , 2006 .

[6]  A. Ougolkov,et al.  Targeting GSK-3: a promising approach for cancer therapy? , 2006, Future oncology.

[7]  Xin Lu,et al.  Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. , 2006, Cell research.

[8]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[9]  M. V. Van Dyke,et al.  Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2. , 2006, EMBO reports.

[10]  A. Baldwin,et al.  Glycogen Synthase Kinase 3β Functions To Specify Gene-Specific, NF-κB-Dependent Transcription , 2005, Molecular and Cellular Biology.

[11]  R. Schwabe,et al.  IKKβ phosphorylates p65 at S468 in transactivaton domain 2 , 2005 .

[12]  Bin Zhang,et al.  Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. , 2005, Biochemical and biophysical research communications.

[13]  M. Ozturk,et al.  Lithium‐mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells , 2005, International journal of cancer.

[14]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[15]  A. Baldwin,et al.  Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. , 2005, Molecular and cellular biology.

[16]  Klaus Resch,et al.  Phosphorylation of Serine 468 by GSK-3β Negatively Regulates Basal p65 NF-κB Activity* , 2004, Journal of Biological Chemistry.

[17]  J. Waxman,et al.  Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth , 2004, Oncogene.

[18]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[19]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[20]  Klaus Resch,et al.  Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. , 2004, The Journal of biological chemistry.

[21]  P. Sandy,et al.  Glycogen Synthase Kinase-3β Regulates NF-κB1/p105 Stability* , 2003, Journal of Biological Chemistry.

[22]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[23]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[24]  P. Sandy,et al.  Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. , 2003, The Journal of biological chemistry.

[25]  A. Arlt,et al.  Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. , 2003, Oncogene.

[26]  David A. Brenner,et al.  Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes , 2002 .

[27]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[28]  C. Rosty,et al.  Molecular pathogenesis of pancreatic cancer. , 2002, Hematology/oncology clinics of North America.

[29]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[30]  R. Schwabe,et al.  Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[31]  R. Urrutia Emerging cellular and molecular themes in pancreatic cancer research , 2002, International journal of gastrointestinal cancer.

[32]  H. Kalthoff,et al.  Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin , 2001, Oncogene.

[33]  P. Polakis Wnt signaling and cancer. , 2000, Genes & development.

[34]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[35]  S. Kern Molecular genetic alterations in ductal pancreatic adenocarcinomas. , 2000, The Medical clinics of North America.

[36]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[37]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[38]  Christoph W. Turck,et al.  Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3 , 1997, Science.

[39]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[40]  P. Polakis,et al.  Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. , 1996, Science.

[41]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[42]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.